Cushing’s Syndrome Treatment Research Highlights: ENDO 2024Continuing Education

This continuing education activity is provided by AffinityCE and CheckRare CE. This activity provides continuing education credit for physicians. A statement of participation is available for other attendees. Estimated time to complete: 0.50 hoursTo obtain CME credit, go to https://checkrare.com/learning/p-cushings-syndrome-treatment-research-highlights-endo-2024/

Commercial Support
Educational Support for this activity was provided by Recordati Rare Diseases, Inc., and Xeris Pharmaceuticals.

Learning Objective
After participating in the activity, learners should be better able to:

• Describe the latest research being presented to better manage individuals with Cushing’s syndrome and its clinical relevance.
• Share new information with their clinical team. 

Activity Description
This 30-minute CME program highlights the latest clinical research about Cushing’s syndrome and Cushing’ disease.Cushing’s syndrome is rare endocrine disorder characterized by chronic hypercortisolism. It is often due to a pituitary adenoma producing excessive ACTH leading to hypercortisolism. Symptoms can range from mild to extensive.This CME program, hosted by Maria Fleseriu, MD, FACE, Professor of Medicine and Neurological Surgery, Director of the Pituitary Center at Oregon Health & Science University, provides an overview of the latest clinical research presented at ENDO 20234 involving Cushing’s syndrome. 

Faculty
Maria Fleseriu, MD, FACE
Professor of Medicine and Neurological Surgery
Director of Pituitary Center
Oregon Health & Science University
Portland, Oregon


Disclosure Statement
AffinityCE and CheckRare CE staff, as well as planning and review committees, have no financial interests to disclose. 

Faculty Educators
Dr. Fleseriu discloses the following relevant financial relationships with ineligible companies to disclose:

• Funding to the University as Principle Investigator from Sparrow Pharmaceuticals
• Scientific consultant for Crinetics Pharmaceuticals, Recordati Rare Diseases, Sparrow Pharmaceuticals, and Xeris Pharmaceuticals

Mitigation of Relevant Financial Relationships 
AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre- and post-program assessments. Your certificate will be emailed to you in within 30 days.

Participation Costs
There is no cost to participate in this CME session. To receive CME credit for your participation, please complete the pre- and post-program assessments. Your certificate will be emailed to you in within 30 days.

CME Inquiries
For all CME policy-related inquiries, please contact us at ce@affinityced.com.
Send customer support requests to cds_support+ldrtc@affinityced.com.

Copyright© 2024. This CME-certified activity is held as copyrighted © by AffinityCE and CheckRare CE. Through this notice, AffinityCE and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).